Why is the FDA restricting BPC-157 and other peptides?

Trying to keep up with what the government thinks about peptides is a bit like trying to catch a greased pig. Just when you think you have a handle on it, things move. As of March 2026, the FDA is keeping a very close eye on several popular substances.

Why are some peptides being restricted?

You might have noticed some of your favorites are getting harder to find. The FDA has moved several peptides into Category 2, which basically means they think there is a significant safety risk and they shouldn't be routinely made by compounding pharmacies (special labs that mix custom medications).

Here is a quick look at why the FDA is waving yellow flags:

• BPC-157: The FDA cites concerns about immunogenicity (the risk of your immune system overreacting to the drug) and a general lack of safety data.
• TB-500: Like BPC-157, this one has immunogenicity risks and no data on how it affects humans.
• CJC-1295: This was removed from general compounding because of safety issues like an increased heart rate.
• GHK-Cu and GHRP-2: Both are also sitting in Category 2 due to concerns about immune system reactions.

What about the peptides actually being studied?

While some peptides are getting the side-eye from regulators, others are moving through massive clinical trials (fancy tests on humans).

Semaglutide has some huge numbers behind it. In the STEP 1 study, people saw 14.9% weight loss. It also showed a 20% reduction in major heart problems during the SELECT trial. However, more use means we see more side effects. The FDA’s safety database (FAERS) has tracked over 187,000 reports for this class of drugs.

Common signals the experts are watching for Semaglutide include:

• Gastrointestinal issues: Nausea, vomiting, and delayed stomach emptying are strong signals.
• Emerging concerns: There are newer reports of Intestinal Obstruction (a blockage in the gut) and NAION (a specific eye condition now under review in Europe).
• Surgical risks: Because it slows down how fast your stomach empties, there is a risk of Pulmonary Aspiration (food or liquid getting into the lungs) during anesthesia.

The "In-Betweeners"

Then there are the peptides that are popular elsewhere but not here. Thymosin Alpha-1 is approved in over 35 countries as Zadaxin, yet it is NOT FDA-approved in the US. In a Phase III trial for sepsis (a severe infection response), it unfortunately showed no reduction in mortality (death rates).

Similarly, Selank and Semax are approved drugs in Russia, but the FDA still has them on the list of substances with safety concerns here.

This is a great one to bring up with your doctor. You can find peptide-experienced physicians in our Find a Doctor directory.

This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.